Fig. 2: Dynamic changes of tumour intrinsic and tumour immune microenvironment molecular features in longitudinal biopsies. | British Journal of Cancer

Fig. 2: Dynamic changes of tumour intrinsic and tumour immune microenvironment molecular features in longitudinal biopsies.

From: PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers

Fig. 2

RNA sequencing transcriptome profiling was done in mandatory tumour biopsy samples collected before treatment, during rucaparib run-in (run-in), and at C2D1 of rucaparib plus atezolizumab (post-combination). a Schematic of biopsy collection timepoints in relation to treatment schedule. b Summary of enriched pathways (Ingenuity pathway analysis) from significantly differentially expressed genes (≥twofold change, P < 0.05) in paired post-combination vs. pre-treatment biopsies. Orange symbols: upregulated gene pathways; blue symbols: downregulated gene pathways. c Dynamic gene expression levels in the PARPi-regulated pathways for DDR, cell cycle, and apoptosis pathways. d Dynamic expression changes in immune signatures for CD274 (PD-L1 gene) and signatures representing CD8 T-cell activity and cGAS-STING. Each line plot in (c, d) represents a patient with confirmed CR or PR (left-hand panels) or SD or PD (right-hand panels). CnDn Cycle n Day n, cGAS cyclic GMP–AMP synthase, CR complete response, DDR DNA damage repair, OC ovarian cancer, PARPi poly(ADP-ribose) polymerase inhibitor, PD progressive disease, PD-L1 programmed cell death-ligand 1, PFS progression-free survival, PR partial response, SD stable disease, STING stimulator of interferon genes, TNBC triple-negative breast cancer.

Back to article page